CKF Tide Tables

CJC-1295 DAC

Quick Facts

PropertyValue
CategoryGrowth Hormone Releasing Hormone Analog
Risk LevelModerate/High
AdministrationSubcutaneous Injection
Typical FrequencyWeekly or Split Twice Weekly
Estimated Half-LifeExtended Long-Acting Peptide
Primary Research InterestGrowth Hormone Signaling / Recovery / IGF-1 Support
Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. CJC-1295 DAC is a biologically active GHRH analog capable of significantly altering growth hormone, IGF-1, metabolic, and recovery signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Reconstitution Guide

  • Vial Size: 5 mg
  • Dilutant Type: BAC Water
  • Amount of Dilutant Added: 2 mL
  • Final Concentration: 2.50 mg/mL

At this concentration:
• 1 mg = 0.400 mL (40.0 units)
• 2 mg = 0.800 mL (80.0 units)

2. Route of Administration

CJC-1295 DAC is most commonly administered as a long-acting subcutaneous injectable GHRH analog.

  • Primary Route: SubQ Injection
  • Preferred Timing: Weekly or split into twice-weekly administration
  • Administration Notes: Frequently researched in conjunction with GHRP compounds and recovery-focused protocols

3. Typical Research Protocols

  • Product Strength: 2.50 mg/mL
  • Typical Delivered Amount: 1–2 mg weekly total
  • Frequency: Weekly or split into twice-weekly administration
  • Cycle Length: 3–6 months on / 1–3 months off
  • Special Notes: CJC-1295 DAC is commonly discussed as a long-acting GHRH analog designed to sustain elevated growth hormone and IGF-1 signaling over extended periods. Compared to shorter-acting secretagogues, the DAC version may produce more stable background elevation rather than sharp pulsatile peaks. Researchers frequently combine it with GHRPs such as Ipamorelin, GHRP-2, or Hexarelin in an attempt to amplify growth hormone release pathways. Because prolonged elevation of growth hormone and IGF-1 may increase risks related to insulin sensitivity, water retention, and tissue growth signaling, conservative dosing and periodic reassessment are commonly emphasized.

4. Summary

CJC-1295 DAC is an experimental long-acting GHRH analog researched for its potential effects on sustained growth hormone signaling, recovery enhancement, IGF-1 support, and body composition pathways.

Research interest in CJC-1295 DAC commonly centers around recovery optimization, performance-oriented applications, sleep support, and anabolic signaling enhancement.

5. Mechanism of Action

CJC-1295 DAC functions by stimulating growth hormone releasing hormone pathways and prolonging growth hormone signaling activity through DAC-mediated half-life extension.

  • Growth hormone signaling enhancement
  • IGF-1 pathway support
  • Recovery signaling support
  • Potential sleep-quality enhancement
  • Metabolic pathway modulation
  • Extended-duration peptide activity

The DAC modification substantially increases peptide duration compared to shorter-acting GHRH analogs.

6. Potential Benefits

  • Potential increase in growth hormone signaling
  • Enhanced recovery support
  • Possible sleep-quality improvements
  • Potential body composition support
  • Possible connective tissue recovery support
  • Potential synergistic effects with GHRP compounds

7. Potential Risks / Side Effects

Moderate/High

  • Water retention
  • Numbness or tingling
  • Fatigue
  • Potential insulin sensitivity changes
  • Elevated IGF-1 signaling
  • Possible joint discomfort
  • Potential tissue growth concerns with prolonged excessive use

8. Half-Life

CJC-1295 DAC is commonly discussed as having a substantially prolonged half-life compared to shorter-acting GHRH analogs.

The DAC modification allows sustained receptor activity and prolonged elevation of downstream growth hormone signaling pathways.

9. Storage Information

  • Store refrigerated before and after reconstitution
  • Protect from direct light exposure
  • Avoid repeated freeze-thaw cycles
  • Maintain sterile handling practices during preparation

10. Contraindications / Warnings

  • Active cancer concerns
  • Uncontrolled diabetes
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptide compounds
  • Use alongside multiple hormone-modulating compounds without supervision

11. Research References

  • PubMed
  • NIH Publications
  • Endocrinology literature
  • Peer-reviewed growth hormone and metabolism journals